COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...
A phase three clinical trial that UT Southwestern participated in determined that a three-drug combination improved lung function and reduced symptoms in cystic fibrosis (CF) patients who have a ...
The mucus in the airways is not as sticky, inflammation in the lungs significantly reduced: Triple combination therapy can achieve these positive, lasting effects in patients with cystic fibrosis (CF) ...
CAMBRIDGE, Mass., Jun 28, 2012 --- Adverse events were similar between treatment and placebo groups; most events were mild to moderate - --- Pivotal program to evaluate VX-809 (600mg) in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback